Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cytokinetics (CYTK) Consolidated Net Income: 2009-2025

Historic Consolidated Net Income for Cytokinetics (CYTK) over the last 16 years, with Sep 2025 value amounting to -$178.1 million.

  • Cytokinetics' Consolidated Net Income fell 18.95% to -$178.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$602.1 million, marking a year-over-year decrease of 7.41%. This contributed to the annual value of -$573.9 million for FY2024, which is 9.43% down from last year.
  • According to the latest figures from Q3 2025, Cytokinetics' Consolidated Net Income is -$178.1 million, which was down 47.96% from -$120.4 million recorded in Q2 2025.
  • Over the past 5 years, Cytokinetics' Consolidated Net Income peaked at -$13.7 million during Q2 2022, and registered a low of -$178.1 million during Q3 2025.
  • Over the past 3 years, Cytokinetics' median Consolidated Net Income value was -$134.6 million (recorded in 2023), while the average stood at -$141.1 million.
  • Its Consolidated Net Income has fluctuated over the past 5 years, first plummeted by 6,173.01% in 2021, then spiked by 76.76% in 2022.
  • Over the past 5 years, Cytokinetics' Consolidated Net Income (Quarterly) stood at -$25.9 million in 2021, then tumbled by 417.27% to -$134.1 million in 2022, then dropped by 0.37% to -$134.6 million in 2023, then fell by 9.95% to -$148.0 million in 2024, then declined by 18.95% to -$178.1 million in 2025.
  • Its Consolidated Net Income stands at -$178.1 million for Q3 2025, versus -$120.4 million for Q2 2025 and -$155.6 million for Q1 2025.